@ldandersonjr Profile picture

Larry Anderson,MD,PhD,FACP

@ldandersonjr

Myeloma, Waldenstroms, Amyloidosis, CAR-T and Cellular Therapy Specialist at UT Southwestern Medical Center (tweets are my own)

Similar User
Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 photo

@szusmani

Sagar Lonial MD photo

@SagarLonialMD

C. Ola Landgren, M.D. photo

@DrOlaLandgren

Craig Hofmeister photo

@EagleMyeloma

Robert Z. Orlowski photo

@Myeloma_Doc

Philip McCarthy photo

@PLMcCarthyMD

Tom Martin photo

@TomBmt133

Joseph Mikhael photo

@jmikhaelmd

Muzaffar Qazilbash photo

@Transplant_Doc

Luciano J Costa photo

@End_myeloma

Suzanne Lentzsch, MD, PhD photo

@SLentzsch

Jim Omel photo

@IMFjimMYELOMA

Dr. Jeffrey Zonder photo

@Amyloid_Planet

Ajay Nooka, MD, MPH photo

@AjayNookaMD

Morie Gertz photo

@MorieGertz

Larry Anderson,MD,PhD,FACP Reposted

🎉 We are proud to recognize our outstanding HemeOnc faculty who have been named on D Magazine's Annual List of Area’s Best Doctors! Congrats to all who made the list! @ldandersonjr @SuzanneColeMD Robert Collins, MD @madanatyazan Namrata Peswani, MD Kevin Courtney, MD

Tweet Image 1

Larry Anderson,MD,PhD,FACP Reposted

Register now for our 2024 Oncology Year in Review CME event on Dec. 7! This program will provide participants with the latest information available as presented at the 2024 @ASCO meeting, 2024 @myESMO meeting, and major findings from other meetings that took place in 2024 from…

Tweet Image 1
Tweet Image 2

When in Rio! UT Southwestern Myeloma team. Looking for another Myeloma specialist to join the fun! #IMS24 #MMSM

Tweet Image 1

Dara/Len vs Len as maintenance after ASCT in newly Dx myeloma: the AURIGA study (Dara/Len significantly improved MRD-negative conversion rate). #mmsm @PlasmaCellPete @utswcancer @Ccostello7 ashpublications.org/blood/article/…


Larry Anderson,MD,PhD,FACP Reposted

#Myeloma Paper of the Day: Phase 3 AURIGA study of Dara/Rev vs. Rev maintenance in newly diagnosed MM post-ASCT w/ ≥VGPR/MRD+ & anti-CD38 naïve shows Dara/Rev superior w/ 47% reduction in risk of PD or death though more cytopenias & infections: pubmed.ncbi.nlm.nih.gov/39331724/. #mmsm

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Larry Anderson,MD,PhD,FACP Reposted

#IMS24 so proud to see #dorishansen (one of our fearless consortium leaders!!) reporting what many thought was impossible… An IPTW matched analysis of real-world #MMsm pts who received cilta-cel vs ide-cel. 🧵 part 1 - set up and population, even matched for study & time!!

Tweet Image 1
Tweet Image 2

Larry Anderson,MD,PhD,FACP Reposted

#IMS24 the US #MMsm immunotherapy consortium is growing and I could not be happier to see it! @SurbhiSidanaMD @DrKrinaPatel @bhemato @PlasmaCellPete @ldandersonjr @BiranNoa @khouri_jack @AimazAfrough - missing @AlGarfall @GKaurMD and many more!

Tweet Image 1

Best meeting of #IMS24! Thanks @SurbhiSidanaMD @DrKrinaPatel #dorishansen for leading this endeavor and so many sub-projects 🙏 Cc @PlasmaCellPete @ldandersonjr @AimazAfrough @BiranNoa and many more!

Tweet Image 1


Larry Anderson,MD,PhD,FACP Reposted

It was great to see everyone at the immunotherapy consortium meeting today! #IMS2024 A powerhouse team for generating real world data in immunotherapy in myeloma.

Tweet Image 1

Best meeting of #IMS24! Thanks @SurbhiSidanaMD @DrKrinaPatel #dorishansen for leading this endeavor and so many sub-projects 🙏 Cc @PlasmaCellPete @ldandersonjr @AimazAfrough @BiranNoa and many more!

Tweet Image 1


Larry Anderson,MD,PhD,FACP Reposted

UT Southwestern is proud to be ranked by U.S. News & World Report as the No. 1 hospital in DFW for the eighth straight year, as well as one of the nation’s top 25 centers for cancer care.

Tweet Image 1

Larry Anderson,MD,PhD,FACP Reposted

UT Southwestern is proud to be named by U.S. News & World Report as the No. 1 hospital in DFW for the eighth straight year, with the most nationally ranked specialties of any hospital in Texas. bit.ly/3y7j4q3

Tweet Image 1

Larry Anderson,MD,PhD,FACP Reposted

Out now in Journal of Hematology and Oncology: Impact of Extramedullary Multiple Myeloma on Outcomes with Ide-cel: jhoonline.biomedcentral.com/articles/10.11… @myelomaMD @YiLinMDPhD @DrKrinaPatel @SurbhiSidanaMD #dorishansen @MoffittNews @BioMedCentral Top line results and a brief 🧵 1/

Tweet Image 1

Larry Anderson,MD,PhD,FACP Reposted

Consensus guidelines and recommendations for the management and response assessment of CAR-T cells in clinical practice for rel/ref MM: a report from the IMWG Immunotherapy Committee #mmsm #bmtsm @TomBmt133 @ldandersonjr @szusmani @TheLancetOncol thelancet.com/journals/lanon…


Larry Anderson,MD,PhD,FACP Reposted

Just out: International Myeloma Working Group guidelines CAR-T cell treatment in myeloma. For Limited time: Link to Free copy & more in thread! @TheLancetOncol @YiLinMDPhD @TomBmt133 @szusmani @chngwj @End_myeloma @bdermanmd @mvmateos @jmikhaelmd et al thelancet.com/journals/lanon…


Larry Anderson,MD,PhD,FACP Reposted

And to cap the day- @UTSWMedCenter @UTSWHemeOnc MYELOMA CREW #mmsm

Tweet Image 1
Tweet Image 2

Larry Anderson,MD,PhD,FACP Reposted

Great #mmsm session to close out day 2 of #iwCART24 @VJHemOnc @DrKrinaPatel @ldandersonjr @sridevirajeeve Dr. Damien Green, Dr. Doris Hansen, Dr. Matt Frigault & Dr. Juan Du who joined from China

Tweet Image 1

Larry Anderson,MD,PhD,FACP Reposted

#EBMT24 Bored between sessions and feel like the cacophony around carfilzomib dosing in myeloma #MMsm has become molto FORTE? Help us standardize our field's practice! 12 questions, <3 min. 🙏 to physicians from 28 countries who've already responded! redcap.link/carfilzomib

Tweet Image 1

Larry Anderson,MD,PhD,FACP Reposted

MRD as an official endpoint for accelerated approval ODAC votes 12-0 great work by all congratulations!!


Larry Anderson,MD,PhD,FACP Reposted

Impact of bridging therapy with Ide-cel for myeloma:U.S. Myeloma Immunotherapy Consortium. @BloodCancerJnl Key takeaway: 'Less is more'; exercise caution with intensified/infusional Cy, if feasible. #myeloma #CAR-T shorturl.at/eqyZ5


Loading...

Something went wrong.


Something went wrong.